# CSPC ZhongQi Pharmaceutical Technology trials: 167 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 167 trials with CSPC ZhongQi Pharmaceutical Technology Co., Ltd. as lead sponsor, 36 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.: 167 rows for $8.35, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/cspc-zhongqi-pharmaceutical-technology-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 167
- Recruiting or not yet: 36
- Read on: November 19, 2026

## Trials

The 25 newest of 167, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 3, 2026 | NCT07911579 | A Study of SYH2051 in Combination With Irinotecan Hydrochloride Liposome Injection in Subjects With Advanced Solid Tumors | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911579) |
| September 11, 2026 | NCT07814651 | A Clinical Trial to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Octreotide Long-acting Injection in Patients With... | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 | Completed | Acromegaly | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814651) |
| September 4, 2026 | NCT07805135 | A Study of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 3 | Not yet recruiting | HER2-Negative Advanced Breast Cancer | 430 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07805135) |
| September 1, 2026 | NCT07798193 | A Study of SYH2085 Tablets Compared With Placebo in Chinese Adult Patients With Uncomplicated Influenza. | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 | Not yet recruiting | Influenza | 213 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07798193) |
| August 11, 2026 | NCT07756996 | Evaluation of Bioequivalence and Food Effect of a New Strength Formulation of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy... | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 | Recruiting | Healthy Participants | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07756996) |
| July 10, 2026 | NCT07694869 | A Phase I Clinical Trial to Evaluate the Pharmacokinetic Characteristics of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants... | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 | Recruiting | Healthy Participants, Participants With Moderate Renal Impairment | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07694869) |
| July 10, 2026 | NCT07694843 | A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With... | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 | Recruiting | Healthy Participants, Participants With Mild Hepatic Impairment, Participants With Moderate Hepatic Impairment | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07694843) |
| July 9, 2026 | NCT07692776 | SYH2095 for Advanced Malignant Tumors: Phase I Study | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Observational | Not yet recruiting | Advanced Malignant Tumors | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07692776) |
| July 6, 2026 | NCT07684287 | A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 | Not yet recruiting | Epithelioid Hemangioendothelioma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07684287) |
| June 3, 2026 | NCT07623824 | A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 3 | Not yet recruiting | Diagnosed With Acromegaly, Currently in the Active Stage of the Disease | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623824) |
| April 16, 2026 | NCT07532655 | A Single Ascending Dose and Multiple Ascending Doses Study of SYH2082 Injection in Healthy Participants | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 | Recruiting | Overweight or Obesity | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07532655) |
| April 2, 2026 | NCT07508501 | Food-effect Study of Ammoxetine Hydrochloride Enteric-coated Tablets | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 | Completed | Healthy Participants | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07508501) |
| April 2, 2026 | NCT07508462 | A Clinical Trial to Evaluate the Effect of Food on the Pharmacokinetics of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy... | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 | Completed | Healthy Participants | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07508462) |
| February 18, 2026 | NCT07418736 | A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 | Recruiting | Chronic Obstructive Pulmonary Disease | 318 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07418736) |
| February 17, 2026 | NCT07412353 | A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 | Recruiting | Healthy Participants | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07412353) |
| December 15, 2025 | NCT07282509 | Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver... | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1/2 | Not yet recruiting | Advanced Hepatocellular Carcinoma (HCC) | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07282509) |
| November 21, 2025 | NCT07241936 | A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1/2 | Recruiting | Advanced Solid Tumors | 444 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07241936) |
| September 10, 2025 | NCT07165886 | Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic... | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2/3 | Recruiting | Gastroenteropancreatic Neuroendocrine Tumors | 298 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07165886) |
| September 9, 2025 | NCT07163364 | A Study to Evaluate the Effects and Safety of Hydroxocobalamin in Participants With Combined Methylmalonic Academia (cblC Type) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 3 | Not yet recruiting | Methylmalonic Acidemia (MMA) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07163364) |
| August 12, 2025 | NCT07117435 | Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver... | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 | Recruiting | Colorectal Liver Metastases, First-line Treatment | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07117435) |
| August 12, 2025 | NCT07116824 | HB1801 Combined Treatment of HER2-positive Breast Cancer | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 | Not yet recruiting | HER2-positive Breast Cancer | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07116824) |
| July 24, 2025 | NCT07083505 | A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 | Not yet recruiting | Advanced Breast Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07083505) |
| May 4, 2025 | NCT06957379 | Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who... | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 | Active not recruiting | HR+/HER2- Advanced/Metastatic Breast Cancer | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06957379) |
| April 27, 2025 | NCT06947291 | Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric... | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 | Recruiting | Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06947291) |
| April 23, 2025 | NCT06941142 | A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 | Not yet recruiting | Advanced Breast Cancer | 382 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06941142) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 73 |
| Phase 1/2 | 14 |
| Phase 2 | 47 |
| Phase 2/3 | 3 |
| Phase 3 | 26 |
| Not applicable | 1 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Unknown | 79 |
| Completed | 35 |
| Not yet recruiting | 19 |
| Recruiting | 17 |
| Terminated | 11 |
| Suspended | 3 |
| Active not recruiting | 2 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus, Type 2 | 9 |
| Leukemia, Myeloid, Acute | 6 |
| Recurrence | 5 |
| Depressive Disorder, Major | 4 |
| Breast Neoplasms | 4 |
| Neoplasms | 4 |
| Lymphoma | 4 |
| Stomach Neoplasms | 3 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Triple Negative Breast Neoplasms | 2 |
| Head and Neck Neoplasms | 2 |
| Cough | 2 |
| Ovarian Neoplasms | 2 |
| Lymphoma, Extranodal NK-T-Cell | 2 |
| Pancreatic Neoplasms | 2 |
| Pulmonary Disease, Chronic Obstructive | 2 |
| Depression | 2 |
| Influenza, Human | 2 |
| Uterine Cervical Neoplasms | 2 |
| Lymphoma, Large B-Cell, Diffuse | 2 |
| Acromegaly | 2 |
| Small Cell Lung Carcinoma | 2 |
| Lymphoma, T-Cell, Peripheral | 2 |
| Invasive Fungal Infections | 1 |
| Perivascular Epithelioid Cell Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Osteopathic practices in the United States](https://specstream.ai/data/businesses/osteopathic-practices/united-states)
- [Dominican restaurants in the United States](https://specstream.ai/data/businesses/dominican-restaurants/united-states)
- [Trailer rental companies in the United States](https://specstream.ai/data/businesses/trailer-rental-companies/united-states)
- [Laboratories in the United States](https://specstream.ai/data/businesses/laboratories/united-states)
- [Business schools in the United States](https://specstream.ai/data/businesses/business-schools/united-states)
